Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
1.955
-0.005 (-0.26%)
Nov 21, 2024, 10:59 AM EST - Market open
Caribou Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 11.48 | 34.48 | 13.85 | 9.6 | 12.36 | 5.79 |
| Revenue Growth (YoY) | -66.85% | 148.91% | 44.31% | -22.35% | 113.56% | - |
| Cost of Revenue | 130.97 | 112.08 | 82.23 | 52.26 | 34.43 | 23.64 |
| Gross Profit | -119.49 | -77.6 | -68.38 | -42.66 | -22.06 | -17.85 |
| Selling, General & Admin | 41.79 | 38.46 | 38.02 | 24.32 | 14.06 | 16.46 |
| Operating Expenses | 41.79 | 38.46 | 38.02 | 24.32 | 14.06 | 16.46 |
| Operating Income | -161.28 | -116.06 | -106.4 | -66.98 | -36.12 | -34.31 |
| Interest Expense | - | - | - | - | -0.02 | -0 |
| Interest & Investment Income | 1.65 | - | - | - | 0.24 | 1.05 |
| Other Non Operating Income (Expenses) | 15.73 | 14.19 | 7.18 | -1.21 | 0.51 | - |
| EBT Excluding Unusual Items | -143.9 | -101.87 | -99.22 | -68.19 | -35.39 | -33.26 |
| Gain (Loss) on Sale of Investments | -0.13 | -0.01 | -0.13 | - | -0.73 | 2.29 |
| Other Unusual Items | - | - | - | 1.58 | - | - |
| Pretax Income | -147.93 | -101.88 | -99.35 | -66.6 | -36.13 | -30.97 |
| Income Tax Expense | 0.19 | 0.19 | 0.07 | 0.32 | -1.82 | -7.54 |
| Net Income | -148.12 | -102.07 | -99.42 | -66.92 | -34.31 | -23.43 |
| Net Income to Common | -148.12 | -102.07 | -99.42 | -66.92 | -34.31 | -23.43 |
| Shares Outstanding (Basic) | 90 | 74 | 61 | 32 | 9 | 8 |
| Shares Outstanding (Diluted) | 90 | 74 | 61 | 32 | 9 | 8 |
| Shares Change (YoY) | 34.02% | 21.39% | 92.02% | 270.47% | 2.05% | - |
| EPS (Basic) | -1.65 | -1.38 | -1.64 | -2.11 | -4.01 | -2.80 |
| EPS (Diluted) | -1.65 | -1.38 | -1.64 | -2.11 | -4.01 | -2.80 |
| Free Cash Flow | -130.75 | -104.9 | -97.42 | -34.64 | -33.53 | -32.89 |
| Free Cash Flow Per Share | -1.46 | -1.42 | -1.60 | -1.09 | -3.92 | -3.93 |
| Gross Margin | - | -225.07% | - | - | -178.50% | - |
| Operating Margin | -1405.52% | -336.63% | -768.17% | -697.84% | -292.24% | -592.69% |
| Profit Margin | -1290.81% | -296.05% | -717.79% | -697.26% | -277.55% | -404.82% |
| Free Cash Flow Margin | -1139.42% | -304.27% | -703.34% | -360.91% | -271.27% | -568.24% |
| EBITDA | -157.8 | -112.53 | -104.78 | -66 | -35.22 | -33.55 |
| EBITDA Margin | - | - | - | - | -284.96% | - |
| D&A For EBITDA | 3.48 | 3.53 | 1.62 | 0.98 | 0.9 | 0.75 |
| EBIT | -161.28 | -116.06 | -106.4 | -66.98 | -36.12 | -34.31 |
| EBIT Margin | - | - | - | - | -292.24% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.